维生素B12联合抗病毒药物治疗深层单疱病毒性角膜炎

目的:观察维生素B12球结膜下注射联合抗病毒药物治疗深层单疱病毒性角膜炎的疗效。方法:63例深层单疱病毒性角膜炎,随机分为观察组和对照组。观察组33眼,应用维生素B12球结膜下注射和阿昔诺韦(ACV)点眼治疗;对照组30眼,常规抗病毒治疗,3mo后观察结果。结果:观察组与对照组比较,病程明显缩短,治愈率提高,总有效率达94%。结论:应用维生素B12球结膜下注射联合抗病毒药物治疗深层单疱病毒性角膜炎与传统治疗方法相比较,安全,经济,疗效显著。     

球结膜下注射转移因子在治疗单纯疱疹病毒性角膜炎的临床应用

目的观察球结膜下注射转移因子对治疗单纯疱疹病毒性角膜炎（ HSK）的疗效。方法86例（92只眼）HSK患者随机分成两组。 A组（45例49只眼）予球结膜下注射转移因子,B组（41例43只眼）予球结膜下注射α-干扰素及α-干扰素滴眼,两组均常规滴用阿昔洛韦滴眼液。结果 A组疗效优于B组（ P ＜0．05）。结论球结膜下注射转移因子可以提高患眼局部免疫力,配合抗病毒治疗HSK效果好,操作简单,无明显副作用。     

板兰根加地塞米松球结膜下注射治疗单疱角膜炎

板兰根加地塞米松球结膜下注射治疗单疱角膜炎湖南省华容县中医院眼科（４１４２００）刘传龙单疱病毒性角膜炎是一种常见的危害性较大，致盲率较高的眼病之一。目前治疗方法虽多，但疗效不一，且无特效治疗方法。笔者于１９９２年至１９９３年，对门诊单疱病毒性角膜炎患...     

万B洛韦联合重组干扰素αIb治疗单疱病毒性角膜炎

目的　探讨万B洛韦联合重组干扰素αIb 治疗单疱病毒性角膜炎的疗效。方法　对单疱病毒性角膜炎(HSK),按病情分为上皮型,浅基质型,深基质型三类。口服万B洛韦和重组干扰素αIb 滴眼液联合应用,与无环鸟苷滴眼液治疗单疱病毒性角膜炎对比观察。结果　联合用药组有效率达98.33% ,复发率明显低于无环鸟苷治疗组,两组治愈率差异非常显著( x 2= 6.98, P < 0.01)。结论　万B洛韦联合重组干扰素αIb 对无环鸟苷无效的病例,对伴有角膜溃疡的病例,能促进其角膜基质的修复和上皮生长,无过敏或毒性反应,提高了疗效,缩短了疗程,为临床治疗HSK 提供了一个新的途径     

转移因子和病毒唑球结膜下注射治疗单疱角膜炎

转移因子和病毒唑球结膜下注射治疗单疱角膜炎山东省莒南县人民医院眼科（２７６６００）刘莉苍山县人民医院五官科刘静苍山县妇幼保健站刘筠单疱病毒性角膜炎眼科常见病，容易复发，且迁延难愈。我们自１９９３年２月－１９９５年４月使用转移因子，病毒唑球结膜下注射，...     

α-干扰素对单疱病毒性角膜炎的疗效及抗复发的临床观察

单疱病毒性角膜炎的发病率和致盲率为角膜病的首位，病情顽同，易于复发。我们采用干扰素结膜下注射治疗单疱病毒性角膜炎，取得了良好的效果，报道如下。     

干扰素治疗单疱病毒性角膜炎

近年来,由于抗菌素和类固醇的广泛应用,单疱病毒性角膜炎的发病数和严重性较以往有增高的趋势,且多数患者反复发作,病程迁延,常导致严重的视功能损害.70年代以来,国外已有应用外源性干扰素治疗单疱病毒性角膜炎的临床报告,且疗效显著.我科亦于近三年内应用干扰素治疗本病,现将临床应用结果报告于下: 一、病例情况与分型近三年内,经我院眼科门诊诊断为单疱病毒性角膜炎并能配合用干扰素治疗的病人73例共90只眼.计男性40例、女性33     

聚肌胞联合维生素C微量皮质类固醇治疗单疱性角膜炎

聚肌胞联合维生素Ｃ微量皮质类固醇治疗单疱性角膜炎福建泉州市国专医院眼科姚照华作者自１９９０年始用干扰素诱导剂聚肌胞联合维生素Ｃ微量地塞米松结膜下注射治疗单疱病毒性角膜炎４２例（４４眼），取得较满意的效果，现报告如下：一、一般情况：本组４２例（４４眼）...     

中西医结合治疗单疱病毒性角膜炎

目的观察应用中西医结合方法治疗单疱病毒性角膜炎的临床疗效。方法应用中西医结合方法治疗25例（27眼）单疱病毒性角膜炎患者，观察并分析治疗结果。结果浅层型治愈率100％，平均治愈天数7．9天。深层型治愈率80％，平均治愈天数16．1天。结论应用中西医结合治疗本病，可缩短病程、降低复发率、保护视功能，取得显著的临床效果。     

典必殊联合阿昔洛韦治疗单疱病毒性角膜炎的疗效观察

目的:探讨典必殊滴眼液联合阿昔洛韦(无环鸟苷,ACV)滴眼液治疗单疱病毒性角膜炎(herpes simplex keratitis,HSK)的疗效。方法:将43例46眼HSK患者随机分两组,典必殊治疗组23例25眼,贝复舒对照组20例21眼,将其临床资料进行回顾性分析,观察临床治疗效果。结果:浅层型全部治愈,深层型典必殊治疗组有效率87.5%,贝复舒对照组有效率60.0%,治愈时间典必殊治疗组平均12d,贝复舒治疗组平均17d;复发率典必殊治疗组34.8%,贝复舒对照组55.0%。两组相比差异有统计学意义(P<0.05)。结论:典必殊联合阿昔洛韦治疗HSK,具有明显的协同作用,能提高治愈率,缩短病程,降低复发,尤其对深层型单疱病毒性角膜炎疗效显著。     

益气养血祛风法治疗复发性单纯疱疹病毒性角膜炎的临床观察

目的:观察运用益气养血祛风法(黑睛退翳汤)治疗复发性单纯疱疹病毒性角膜炎(HSK)的临床疗效.方法:入选复发的HSK患者58例,随机分为治疗组和对照组.对照组给予重组人干扰素α-2b滴眼液和更昔洛韦眼用凝胶,对于具有虹膜睫状体炎症及角膜内皮炎症的患者给予复方托吡卡胺滴眼液散瞳治疗,酌情给予氟米龙滴眼液滴眼;治疗组在对照组的基础上加用黑睛退翳汤治疗4wk,观察两组临床疗效及治愈的患者治愈后6mo内疾病复发率情况.结果:两组患者治疗后临床疗效、疾病复发率比较差异均有统计学意义(P<0.05),治疗1 mo后,治疗组CD4+及CD4+/CD8+比值明显升高,均显著高于对照组(P<0.01),治疗组CD8+比例显著降低,与对照组比较差异显著(P<0.01).结论:益气养血祛风法中药黑睛退翳汤联合常规抗病毒西药治疗,能更好地治疗HSK并预防其复发,提高临床疗效,改善患者生活质量.     

单纯疱疹病毒性角膜炎药物联合治疗的临床观察

目的评价华蟾素联合阿糖胞苷注射液和无环鸟苷滴眼液治疗单纯疱疹病毒性角膜炎的疗效。方法将186例(200只眼)单纯疱疹性病毒角膜炎患者随机分为治疗组106例和对照组94例,治疗组采用静脉滴注华蟾素、结膜下注射阿糖胞苷注射液和结膜囊滴用无环鸟苷滴眼液联合治疗。对照组采用上述三种治疗方法中的一种或两种。结果治疗组第一疗程治疗时间最长10天,最短3天,平均6天痊愈,治愈率为94.3％,而对照组治疗时间最长40天,最短7天,平均15．2天,治愈率为64．9％,两组相比差异有显著性(P<0．05)。结论本方法能明显缩短疗程,减少瘢痕形成,提高治愈率。     

抗病毒药联合免疫增强剂治疗单疱病毒性角膜炎的临床与免疫学评价

用抗病毒药联合免疫增强剂对41例单疱病毒性角膜炎患者进行治疗。A 组患者(21例)用无环鸟苷、干扰素和转移因子治疗,B 组患者(20例)用无环鸟苷和干扰素治疗。结果A 组的复发率明显低于B组(P<0.05)。治愈后,A 组的淋巴细胞转化率(LTR)与E-玫瑰花结形成细胞(E-RFC)接近对照组水平(P>0.05),B 组的LTR 与E-RFC 则明显低于对照组与A 组水平(P<0.05)。提示转移因子能降低HSK 的复发率,并能提高HSK 患者的细胞免疫功能。     

深板层角膜移植术治疗单纯疱疹病毒性角膜炎的临床研究

目的评价深板层角膜移植术治疗单纯疱疹性角膜炎的临床效果。方法对临床确诊为单疱病毒性角膜炎且经抗病毒药物治疗无效的患者,根据角膜炎累及角膜范围及深度选择深板层角膜移植术,共18例18眼。术后随访时间为12～36个月。观察术后视力、植片的透明度、复发率及术中术后并发症情况。结果18例中17例视力均有不同程度的恢复,矫正视力0．1～0．8,其中12例植片透明,5例植片轻度浑浊,1例角膜炎复发。结论深板层角膜移植是治疗单疱病毒性角膜炎的有效手术方法。     

更昔洛韦眼用凝胶联合脾氨肽治疗上皮型单纯疱疹病毒性角膜炎

目的：观察更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型单纯疱疹病毒性角膜炎(HSK)的效果。

方法：选取2015-01/2016-06在我院眼科门诊确诊的70例70眼HSK患者,随机分为对照组和试验组。两组患者均采用更昔洛韦眼用凝胶治疗,试验组在此基础上口服脾氨肽冻干粉。两组患者连续用药30d。比较两组患者的临床治愈率、角膜溃疡愈合时间、疼痛减轻时间、畏光消失时间、视力改善情况及复发率等。

结果：治疗30d后,试验组患者临床治愈率(80%)显著高于对照组(51%),差异有统计学意义(P<0.05)。与对照组相比,试验组患者角膜溃疡愈合时间、疼痛缓解时间及畏光消失时间均缩短,差异均有统计学意义(P<0.05)。随访1a,试验组患者复发率为14%,对照组为67%,试验组复发率低于对照组,差异有统计学意义(P<0.05)。

结论：更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型HSK疗效好,能显著提高视力及临床治愈率,缩短病程,降低复发率。     

深层型单疱病毒性角膜炎药物治疗临床研究

目的:探讨深层型单疱病毒性角膜炎药物治疗的有效方法。方法:40例50眼,患者随机分为两组,治疗组应用1g/L无环鸟苷和贝复舒眼用凝胶,对照组仅给予1g/L无环鸟苷,6次/d滴眼。结果:治疗组25眼,有效率96%,平均治疗10d,对照组25眼,有效率73%,平均治疗30d;两组有效率与治疗时间比较,差异有显著性(P<0.01)。结论:贝复舒眼用凝胶联合无环鸟苷治疗单疱病毒性角膜炎具有明显的协同作用,可大大缩短病程,提高治愈率。     

Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%

PURPOSE: To assess the efficacy of topical cyclosporine 0.05% (Restasis) in patients with herpes simplex virus nonnecrotizing stromal keratitis unresponsive to topical prednisolone. DESIGN: Prospective case series. METHODS: Patients with herpes simplex virus stromal keratitis (n = 12) that was unresponsive to topical prednisolone acetate 1% for at least four weeks were evaluated at a single site. Eyes were treated with topical cyclosporine twice a day and begun on a rapid prednisolone taper. Visual acuity, slit-lamp appearance, intraocular pressure, and corneal sensitivity were evaluated every two weeks for at least three months. RESULTS: Stromal keratitis resolved with cyclosporine in 10 of 12 patients after one month. The mean lesion area decreased more with cyclosporine than with prednisolone (2.0 mm with cyclosporine compared with 0.25 mm with prednisolone). After stopping cyclosporine therapy, four patients had recurrence of stromal keratitis. CONCLUSION: This series suggests that herpes simplex virus stromal keratitis can be treated effectively with topical cyclosporine, particularly in cases that are not responsive to topical prednisolone.     

膦甲酸钠滴眼液治疗单纯疱疹性角膜炎的临床研究

目的：观察和比较3％膦甲酸钠和0．1％无环鸟苷滴眼液治疗单纯疱疹性角膜炎的疗效和安全性,方法：对门诊164例单纯疱疹性角膜炎病人进行多中心,双盲,平行组对照和开放试验等方面进行检查治疗。结果：膦甲酸钠组治愈率为65．00％,有效率为85．00％,无环鸟苷组分别为41．27％,69．84％,开放组分别为43．90％和75．61％。经统计学分析：治愈率有统计学显著性（P＝0．01）,有效率有显著性（P＝0．05）,膦甲酸钠滴眼液疗效优于无环鸟苷滴眼液,并未发现全身性毒副作用,仅有轻微一过性眼部刺激,其发生率与对照组相似。结论：膦甲酸钠滴眼液疗效较无环鸟苷滴眼液佳,且使用安全。     

Recurrent herpetic keratitis during topical acyclovir application.

Dendritic herpetic keratitis developed in a 49-year-old patient during topical acyclovir treatment. A positive herpes simplex culture was obtained. After acyclovir was replaced by trifluorothymidine and interferon, the dendritic lesion disappeared and herpes simplex culture became negative. Six months later a carcinoma of the larynx was diagnosed. The acyclovir-resistant herpetic keratitis may be associated with the carcinoma because resistant herpes simplex virus strains are predominantly described in patients suffering from immune deficiency.     

Immunofluorescent staining and corneal sensitivity in patients suspected of having herpes simplex keratitis.

We examined immunofluorescent staining and corneal sensitivity in 25 control subjects (25 eyes) with normal corneas, six patients (eight eyes) with possible herpes simplex keratitis, and 44 patients (48 eyes) with corneal lesions (recurrent erosion, superficial punctate keratitis, marginal ulcer, and follicular keratoconjunctivitis) in whom herpes simplex keratitis was not suspected. On immunofluorescent staining, all 25 control subjects had negative reactions, all eight eyes suspected of having herpes simplex keratitis had positive reactions, and 11 (23%) of the 48 eyes not suspected of having herpes simplex keratitis had positive reactions; the remaining 37 eyes had negative reactions. Of the 11 eyes not suspected of having herpes simplex keratitis but that had positive reactions on immunofluorescent staining, nine had recurrent erosions and the remaining two eyes had superficial punctate keratitis. Of the eight eyes with possible herpes simplex keratitis, seven (88%) had decreased corneal sensitivity. Of the 11 eyes not suspected of having herpes simplex keratitis but that had positive reactions on immunofluorescent staining, eight (73%) had decreased corneal sensitivity. Of the 37 eyes not suspected of having herpes simplex keratitis that had negative reactions on immunofluorescent staining, 11 (30%) had decreased corneal sensitivity.